New pain drug could cut opioid use after pancreatic surgery

NCT ID NCT07423650

Recruiting now Symptom relief Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a continuous infusion of nefopam, a non-opioid painkiller, can reduce opioid use and pain after pancreatoduodenectomy (a major pancreatic surgery). About 93 adults will be randomly assigned to receive nefopam, lidocaine, or standard epidural pain relief. Researchers will measure opioid consumption and pain scores over 48 hours after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nefopam
What this could lead to: If it works, this could offer a better way to manage pain after pancreatic surgery, reducing the need for opioids and their side effects.
What could go wrong: This is a small, early-phase trial focused on pain control, not a cure. The results may not apply to other surgeries or patients, and nefopam may not prove superior to existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIMODAL ANALGESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIMODAL ANALGESIA OPIOID ANALGESIA PAIN MANAGEMENT PANCREATODUODENECTOMY

Contacts and locations

Locations

Prof. O. Fodor Regional Institute of Gastroenterology and Hepatology
RECRUITING

Cluj-Napoca, Cluj, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.